PremiumCompany AnnouncementsViatris Reports Strong 2024 Financial Results Viatris, Inc. Earnings Call: Balancing Growth and Challenges Viatris sees FY25 adjusted EPS $2.12-$2.26, consensus $2.59 PremiumThe FlyViatris announces publication of CARE study results Viatris Elects Directors and Amends Stock Plan at Meeting Viatris price target raised to $14 from $13 at Piper Sandler PremiumThe FlyLexicon signs licensing agreement with Viatris for sotagliflozin Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license Early notable gainers among liquid option names on October 15th 
